Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labo EuromedisFRA:61R -3.76%62 EV-to-EBITDA is 3.48 as of Aug. 23, 2026, which is 26% above its 10-year median of 2.76. GuruFocus rates FRA:61R with a GF Score™ of 62/100 and a GF Value™ of €4.38. The stock has 6 warning signs investors should review. Among 99 Medical Distribution companies, Labo Euromedis ranks better than 89.9% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Labo Euromedis's enterprise value is €3.60 Mil.
Labo Euromedis's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €1.04 Mil. Therefore, Labo Euromedis's EV-to-EBITDA for today is 3.48.
The historical rank and industry rank for Labo Euromedis's EV-to-EBITDA or its related term are showing as below:
FRA:61R'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -75.48 Med: 2.76 Max: 18.04
Current: 3.48
During the past 13 years, the highest EV-to-EBITDA of Labo Euromedis was 18.04. The lowest was -75.48. And the median was 2.76.
FRA:61R's EV-to-EBITDA is ranked better than 89.9% of 99
companies
in the Medical Distribution industry
Industry Median: 8.52
vs FRA:61R: 3.48
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Labo Euromedis's PE Ratio (TTM) for today is calculated as:
Labo Euromedis's share price for today is €4.86.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Labo Euromedis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.046.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Labo Euromedis's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Labo Euromedis's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labo Euromedis EV-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Labo Euromedis's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Labo Euromedis's EV-to-EBITDA falls into.
Labo Euromedis's current Enterprise Value is €3.60 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Labo Euromedis's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €1.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labo Euromedis (FRA:61R) has a EV-to-EBITDA of 3.48 as of Aug. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Labo Euromedis. This is 26% above median its historical median of 2.76. According to the industry distribution chart, Labo Euromedis ranks #10 out of 99 companies in the Medical Distribution industry, placing it in the top 10.1%.
Is Labo Euromedis' EV-to-EBITDA too high?
Labo Euromedis' current EV-to-EBITDA of 3.48 is 26% above median its 10-year median of 2.76. The Medical Distribution industry median EV-to-EBITDA is 8.52. Labo Euromedis' value of 3.48 is 59.2% below this industry median. Based on the distribution chart, Labo Euromedis ranks #10 out of 99 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Labo Euromedis has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Labo Euromedis' EV-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Labo Euromedis ranks #10 out of 99 companies for EV-to-EBITDA. This places Labo Euromedis in the top 10% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 8.52. Labo Euromedis' value of 3.48 is 59.2% below this benchmark. While the company's 10-year median is 2.76 vs. the industry median of 8.52, Labo Euromedis has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Distribution company?
The median EV-to-EBITDA among Medical Distribution companies is 8.52, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labo Euromedis's current EV-to-EBITDA of 3.48 is 59.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Labo Euromedis. For the Medical Distribution industry, the median EV-to-EBITDA is 8.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labo Euromedis's current EV-to-EBITDA is 3.48, which is 26% above median its own 10-year median of 2.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labo Euromedis stock overvalued right now?
Labo Euromedis (FRA:61R) has a current EV-to-EBITDA of 3.48. The stock's GF Value™ is €4.38, compared to a current price of €4.86 — trading 11% above its estimated fair value. The current EV-to-EBITDA is 3.48, which is 26% above median its 10-year median of 2.76 and 59.2% below the Medical Distribution industry median of 8.52. Labo Euromedis' overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Labo Euromedis (FRA:61R), the current EV-to-EBITDA is 3.48 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labo Euromedis (FRA:61R) Overvalued in 2026?
Based on GuruFocus' analysis, Labo Euromedis stock appears to be overvalued.
The current stock price of €4.86 is trading 11% above its estimated GF Value™ of €4.38.
Key valuation signals for FRA:61R:
EV-to-EBITDA: 3.48 (26% above median its 10-year median of 2.76)
GF Value™: €4.38 vs. price of €4.86 (11% above fair value)
Industry Position: 59.2% below the Medical Distribution median (#10 of 99)
No single metric tells the full story. See the FRA:61R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.
62GF Score
Get the complete analysis for FRA:61R
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:61R has been successfully added to your 
